Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Q2 Revenues Increase 17 Percent As Losses Narrow

NEW YORK (GenomeWeb News) – Third Wave Technologies said today that revenues for the second quarter increased approximately 17 percent, including an 18-percent spike in clinical molecular diagnostic receipts, as net losses declined.
 
Third Wave said revenue for the three months ended June 30 increased to $6.8 million from $5.8 million year over year. The company reported $5.1 million in clinical molecular diagnostic revenues and $1.6 million in research revenues.
 
Net loss for the second quarter declined to $4.7 million from $5.5 million in the same quarter one year ago.
 
R&D spending in the period increased to about $3 million from $2 million in the year-ago period.
 
As of June 30, Third Wave had $36.2 million in cash, cash equivalents, and short-term investments.
 
In addition, Third Wave said it would launch its Universal Invader Plus program earlier than anticipated as customer evaluations have progressed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.